Muscular dystrophy drug approved

  • This image provided by Sarepta Therapeutics in December 2019 shows a box and vial of their drug Vyondys 53. On Thursday, Dec. 12, 2019, U.S. health regulators said they approved this second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months earlier. (Sarepta Therapeutics via AP)

WASHINGTON — U.S. health regulators approved a second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months ago.

0 Comments